Daidzein

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Not to be confused with Daidzin.
Daidzein[1]
Daidzein.svg
Diazein molecule
Names
IUPAC name
7-Hydroxy-3-(4-hydroxyphenyl) chromen-4-one
Other names
4',7-Dihydroxyisoflavone
Daidzeol
Isoaurostatin
Identifiers
486-66-8 YesY
3D model (Jmol) Interactive image
ChEBI CHEBI:28197 YesY
ChEMBL ChEMBL8145 YesY
ChemSpider 4445025 YesY
ECHA InfoCard 100.006.942
2828
KEGG C10208 YesY
PubChem 5281708
UNII 6287WC5J2L YesY
Properties
C15H10O4
Molar mass 254.23 g/mol
Appearance Pale yellow prisms
Melting point 315 to 323 °C (599 to 613 °F; 588 to 596 K) (decomposes)
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
YesY verify (what is YesYN ?)
Infobox references

Daidzein structurally belongs to the group of isoflavones.

Natural occurrences[edit]

Daidzein and other isoflavone compounds, such as genistein, are present in a number of plants and herbs like Kwao Krua (Pueraria mirifica) and Kudzu (Pueraria lobata). It can also be found in Maackia amurensis cell cultures.[2]

In food sources[edit]

Daidzein can be found in food such as soybeans and soy products like tofu and textured vegetable protein. Soy isoflavones are a group of compounds found in and isolated from the soybean. Of note, total isoflavones in soybeans are—in general—37 percent daidzein, 57 percent genistein and 6 percent glycitein, according to USDA data.[3] Soy germ contains 41.7 percent daidzein.[4]

Biological activities[edit]

Daidzein can be converted to its end metabolite S-equol in some humans based on the presence of certain intestinal bacteria. Based on several decades of research, S-equol has potential for significant health benefits.

Daidzein has no classification in the United States, where it is not considered to be generally recognized as safe (GRAS),[5] and has not been approved as a drug for any indication. It is a component of foods and dietary supplements derived from soy.[6] Dietary supplements are not regulated as drugs in the U.S., and the labeling of dietary supplements in the U.S. may not describe the supplement as having any drug activity or effectiveness.[7]

Scientists have studied some of the activities of daidzein in their laboratories, working with cells or with animals such as mice. Studies in cells and in animals sometimes give hints as to what a chemical might do when given to humans, but no one can know what a chemical does in humans until the chemical is tested in a clinical trial.

Daidzein has been found to act as an agonist of the GPER (GPR30).[8]

Activation of PPARs[edit]

Daidzein transactivates all three PPAR isoforms, α, δ, and γ and influences target cells.[9]

Cell proliferation studies[edit]

Daidzein has both estrogenic and anti-estrogenic effects. Experiments in cells and in animals showed that lower concentrations stimulate breast tumor growth in in vitro and in vivo, and ihibits the antitumor effect of the cancer drug tamoxifen, but higher concentrations (above 10 μM) have the contrary effect.[10] T47D:A18/PKC alpha tumor growth was demonstrated to be stimulated by genistein, but partially inhibited by daidzein; however, coadministration of tamoxifen with either daidzein or genistein produced tumors of greater size.[11]

Antioxidant[edit]

Scientific studies of daidzein's antioxidant properties have given contradictory results: some studies have shown antioxidant properties in laboratory experiments on cells, but in other experiments daidzein has caused oxidative stress on cells.[12]

Daidzein metabolite S-equol activities[edit]

Daidzein, when consumed from soy, is transformed in some humans, but not all, to produce S-equol [7-hydroxy-3-(49-hydroxyphenyl)-chroman],[13] Because it is a metabolite of daidzein, S-equol is not of plant origin. The molecular and physical structure of S-equol is similar to that of estradiol,[14] the main sex hormone found in women.

The ability to transform daidzein into S-equol is based on the presence of certain intestinal bacteria. In fact, several studies indicate that only 25 to 30 percent of the adult population of Western countries produces S-equol after eating soy foods containing isoflavones,[14][15][16][17] significantly lower than the reported 50 to 60 percent frequency of equol-producers in adults from Japan, Korea, or China.[18][19][20][21]

Although still under investigation, the ability to produce S-equol may be associated with other health benefits, according to data from epidemiological and clinical trials. Studies in both animal models and humans have yielded data about the potential of S-equol use in menopause[22][23] breast and prostate cancer,[14] and bone health.[24][25]

Glycosides[edit]

List of plants that contain the chemical[edit]

References[edit]

  1. ^ Merck Index, 11th Edition, 2805.
  2. ^ Isoflavonoid production by callus cultures of Maackia amurensis. S.A Fedoreyev, T.V Pokushalov, M.V Veselova, L.I Glebko, N.I Kulesh, T.I Muzarok, L.D Seletskaya, V.P Bulgakov and Yu.N Zhuravlev, Fitoterapia, 1 August 2000, Volume 71, Issue 4, Pages 365–372, doi:10.1016/S0367-326X(00)00129-5
  3. ^ "Isoflavones contents of food". Top Cultures. Retrieved 2012-05-15. 
  4. ^ Zhang, Y.; Wang, G. J.; Song, T. T.; Murphy, P. A.; Hendrich, S. (1999). "Urinary disposition of the soybean isoflavones daidzein, genistein and glycitein differs among humans with moderate fecal isoflavone degradation activity". The Journal of Nutrition. 129 (5): 957–962. PMID 10222386. 
  5. ^ FDA GRAS database
  6. ^ Fact Sheet On The Phytoestrogen Daidzein
  7. ^ FDA 101: Dietary Supplements
  8. ^ Prossnitz, Eric R.; Barton, Matthias (2014). "Estrogen biology: New insights into GPER function and clinical opportunities". Molecular and Cellular Endocrinology. 389 (1-2): 71–83. doi:10.1016/j.mce.2014.02.002. ISSN 0303-7207. PMC 4040308Freely accessible. PMID 24530924. 
  9. ^ Dang Z. C.; Löwik, C. (2004). "The Balance between Concurrent Activation of ERs and PPARs Determines Daidzein-Induced Osteogenesis and Adipogenesis". Journal of Bone and Mineral Research. 19 (5): 853–861. doi:10.1359/jbmr.040120. PMID 15068509. 
  10. ^ de Lemos, M. L. (2001). "Effects of soy phytoestrogens genistein and daidzein on breast cancer growth.". Annals of Pharmacotherapy. 35 (9): 11118–11121. doi:10.1345/aph.10257. PMID 11573864. 
  11. ^ Tonetti, D. A.; Zhang, Y.; Zhao, H.; Lim, S. B.; Constantinou, A. I. (2007). "The effect of the phytoestrogens genistein, daidzein, and equol on the growth of tamoxifen-resistant T47D / PKCα". Nutrition and Cancer. 58 (2): 1222–1229. doi:10.1080/01635580701328545. PMID 17640169. 
  12. ^ Röhrdanz, E.; Ohler, S.; Tran-Thi, Q. H.; Kahl, R. (2002). "The Phytoestrogen Daidzein Affects the Antioxidant Enzyme System of Rat Hepatoma H4IIE Cells" (pdf). Journal of Nutrition. 132 (2): 370–375. PMID 11880557. 
  13. ^ Setchell, K. D.; Clerici, C. (2010). "Equol: History, Chemistry, and Formation" (pdf). The Journal of Nutrition. 140 (7): 1355S–1362S. doi:10.3945/jn.109.119776. PMC 2884333Freely accessible. PMID 20519412. 
  14. ^ a b c Atkinson, C.; Frankenfeld, C. L.; Lampe, J. W. (2005). "Gut bacterial metabolism of the soy isoflavone daidzein: exploring the relevance to human health" (pdf). Experimental Biology and Medicine. 230 (3): 155–170. PMID 15734719. 
  15. ^ Lampe, J. W.; Karr, S. C.; Hutchins, A. M.; Slavin, J. L. (1998). "Urinary Equol Excretion with a Soy Challenge: Influence of Habitual Diet". Proceedings of the Society for Experimental Biology and Medicine. 217 (3): 335–339. doi:10.3181/00379727-217-44241. PMID 9492344. 
  16. ^ Setchell, K. D.; Cole, S. J. (2006). "Method of Defining Equol-Producer Status and its Frequency among Vegetarians" (pdf). The Journal of Nutrition. 136 (8): 2188–2193. PMID 16857839. 
  17. ^ Rowland, I. R.; Wiseman, H.; Sanders, T. A.; Adlercreutz, H.; Bowey, E. A. (2000). "Interindividual Variation in Metabolism of Soy Isoflavones and Lignans: Influence of Habitual Diet on Equol Production by the Gut Microflora". Nutrition and Cancer. 36 (1): 27–32. doi:10.1207/S15327914NC3601_5. PMID 10798213. 
  18. ^ Watanabe, S.; Yamaguchi, M.; Sobue, T.; Takahashi, T.; Miura, T.; Arai, Y.; Mazur, W.; Wähälä, K.; Adlercreutz, H. (1998). "Pharmacokinetics of Soybean Isoflavones in Plasma, Urine and Feces of Men after Ingestion of 60 g Baked Soybean Powder (Kinako)" (pdf). The Journal of Nutrition. 128 (10): 1710–1715. PMID 9772140. 
  19. ^ Arai, Y.; Uehara, M.; Sato, Y.; Kimira, M.; Eboshida, A.; Adlercreutz, H.; Watanabe, S. (2000). "Comparison of Isoflavones among Dietary Intake, Plasma Concentration and Urinary Excretion for Accurate Estimation of Phytoestrogen Intake" (pdf). Journal of Epidemiology. 10 (2): 127–135. doi:10.2188/jea.10.127. PMID 10778038. 
  20. ^ Akaza, H.; Miyanaga, N.; Takashima, N.; Naito, S.; Hirao, Y.; Tsukamoto, T.; Fujioka, T.; Mori, M.; Kim, W. J.; Song, J. M.; Pantuck, A. J. (2004). "Comparisons of Percent Equol Producers between Prostate Cancer Patients and Controls: Case-controlled Studies of Isoflavones in Japanese, Korean and American Residents" (pdf). Japanese Journal of Clinical Oncology. 34 (2): 86–89. doi:10.1093/jjco/hyh015. PMID 15067102. 
  21. ^ Song, K. B.; Atkinson, C.; Frankenfeld, C. L.; Jokela, T.; Wähälä, K.; Thomas, W. K.; Lampe, J. W. (2006). "Prevalence of Daidzein-Metabolizing Phenotypes Differs between Caucasian and Korean American Women and Girls" (pdf). The Journal of Nutrition. 136 (5): 1347–1351. PMID 16614428. 
  22. ^ Aso, T.; Uchiyama, S.; Matsumura, Y.; Taguchi, M.; Nozaki, M.; Takamatsu, K.; Ishizuka, B.; Kubota, T.; Mizunuma, H.; Ohta, H. (2012). "A natural S-equol supplement alleviates hot flushes and other menopausal symptoms in equol nonproducing postmenopausal Japanese women". Journal of Women's Health. 21 (1): 92–100. doi:10.1089/jwh.2011.2753. PMID 21992596. 
  23. ^ Jou, H. J.; Wu, S. C.; Chang, F. W.; Ling, P. Y.; Chu, K. S.; Wu, W. H. (2008). "Effect of intestinal production of equol on menopausal symptoms in women treated with soy isoflavones". International Journal of Gynaecology and Obstetrics. 102 (1): 44–49. doi:10.1016/j.ijgo.2008.01.028. PMID 18395723. 
  24. ^ Wu, J.; Oka, J.; Ezaki, J.; Ohtomo, T.; Ueno, T.; Uchiyama, S.; Toda, T.; Uehara, M.; Ishimi, Y. (2007). "Possible role of equol status in the effects of isoflavone on bone and fat mass in postmenopausal Japanese women: a double-blind, randomized, controlled trial". Menopause. 14 (5): 866–874. doi:10.1097/gme.0b013e3180305299. PMID 17464237. 
  25. ^ Tousen, Y.; Ezaki, J.; Fujii, Y.; Ueno, T.; Nishimuta, M.; Ishimi, Y. (2011). "Natural S-Equol Decreases Bone Resorption in Postmenopausal, Non-Equol-Producing Japanese Women: A Pilot Randomized, Placebo-Controlled Trial". Menopause. 18 (5): 563–574. doi:10.1097/gme.0b013e3181f85aa7. PMID 21252728. 
  26. ^ Chen, G.; Zhang, J.; Ye, J. (2001). "Determination of Puerarin, Daidzein and Rutin in Pueraria lobata (Willd.) Ohwi by Capillary Electrophoresis with Electrochemical Detection". Journal of Chromatography A. 923 (1–2): 255–262. doi:10.1016/S0021-9673(01)00996-7. PMID 11510548. 
  27. ^ Xu, H.-N.; He, C.-H. (2007). "Extraction of Isoflavones from Stem of Pueraria lobata (Willd.) Ohwi Using n-Butanol / Water Two-Phase Solvent System and Separation of Daidzein". Separation and Purification Technology. 56 (1): 255–262. doi:10.1016/j.seppur.2007.01.027. 
  28. ^ Zhou, H. Y.; Wang, J. H.; Yan, F. Y. (2007). "[Separation and Determination of Puerarin, Daidzin and Daidzein in Stems and Leaves of Pueraria thomsonii by RP-HPLC]". Zhongguo Zhong Yao Za Zhi (in Chinese). 32 (10): 937–939. PMID 17655152. 
Retrieved from "https://en.wikipedia.org/w/index.php?title=Daidzein&oldid=756586603"